182 related articles for article (PubMed ID: 27070719)
1. Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis.
Bandeira L; Lewiecki EM; Bilezikian JP
Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):681-9. PubMed ID: 27070719
[TBL] [Abstract][Full Text] [Related]
2. Oral salmon calcitonin--pharmacology in osteoporosis.
Henriksen K; Bay-Jensen AC; Christiansen C; Karsdal MA
Expert Opin Biol Ther; 2010 Nov; 10(11):1617-29. PubMed ID: 20932224
[TBL] [Abstract][Full Text] [Related]
3. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
Tankó LB; Bagger YZ; Alexandersen P; Devogelaer JP; Reginster JY; Chick R; Olson M; Benmammar H; Mindeholm L; Azria M; Christiansen C
J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
[TBL] [Abstract][Full Text] [Related]
5. Oral calcitonin.
Maricic MJ
Curr Osteoporos Rep; 2012 Mar; 10(1):80-5. PubMed ID: 22281725
[TBL] [Abstract][Full Text] [Related]
6. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin.
Karsdal MA; Byrjalsen I; Riis BJ; Christiansen C
BMC Clin Pharmacol; 2008 Sep; 8():5. PubMed ID: 18782439
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of salmon calcitonin (sCT) enteric-coated capsule for enhanced absorption and GI tolerability in rats.
Wu L; Zhang G; Lu Q; Sun Q; Wang M; Li N; Gao Z; Sun Y; Li T; Han D; Yu X; Wang L; Sun W; Zhao D; Wu Y; Lu Y; Chen X
Drug Dev Ind Pharm; 2010 Mar; 36(3):362-70. PubMed ID: 19719396
[TBL] [Abstract][Full Text] [Related]
8. Coated minispheres of salmon calcitonin target rat intestinal regions to achieve systemic bioavailability: Comparison between intestinal instillation and oral gavage.
Aguirre TAS; Aversa V; Rosa M; Guterres SS; Pohlmann AR; Coulter I; Brayden DJ
J Control Release; 2016 Sep; 238():242-252. PubMed ID: 27480451
[TBL] [Abstract][Full Text] [Related]
9. Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials.
Karsdal MA; Henriksen K; Bay-Jensen AC; Molloy B; Arnold M; John MR; Byrjalsen I; Azria M; Riis BJ; Qvist P; Christiansen C
J Clin Pharmacol; 2011 Apr; 51(4):460-71. PubMed ID: 20660294
[TBL] [Abstract][Full Text] [Related]
10. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.
Plosker GL; McTavish D
Drugs Aging; 1996 May; 8(5):378-400. PubMed ID: 8935399
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats.
Bhandari KH; Newa M; Chapman J; Doschak MR
J Control Release; 2012 Feb; 158(1):44-52. PubMed ID: 22001608
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
Trovas GP; Lyritis GP; Galanos A; Raptou P; Constantelou E
J Bone Miner Res; 2002 Mar; 17(3):521-7. PubMed ID: 11874243
[TBL] [Abstract][Full Text] [Related]
13. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
[TBL] [Abstract][Full Text] [Related]
14. Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin.
Swaminathan J; Gobbo OL; Tewes F; Healy AM; Ehrhardt C
J Aerosol Med Pulm Drug Deliv; 2014 Feb; 27(1):1-11. PubMed ID: 24252061
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterization and in vitro evaluation of a bone targeting delivery system for salmon calcitonin.
Bhandari KH; Newa M; Uludag H; Doschak MR
Int J Pharm; 2010 Jul; 394(1-2):26-34. PubMed ID: 20412845
[TBL] [Abstract][Full Text] [Related]
16. Calcitonin load test to assess the efficacy of salmon calcitonin.
Stepan JJ; Zikán V
Clin Chim Acta; 2003 Oct; 336(1-2):49-55. PubMed ID: 14500034
[TBL] [Abstract][Full Text] [Related]
17. Hexapeptide-conjugated calcitonin for targeted therapy of osteoporosis.
Liu Y; Yu P; Peng X; Huang Q; Ding M; Chen Y; Jin R; Xie J; Zhao C; Li J
J Control Release; 2019 Jun; 304():39-50. PubMed ID: 31054990
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
Reginster JY; Deroisy R; Lecart MP; Sarlet N; Zegels B; Jupsin I; de Longueville M; Franchimont P
Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
[TBL] [Abstract][Full Text] [Related]
19. Calcitonin.
Silverman SL
Am J Med Sci; 1997 Jan; 313(1):13-6. PubMed ID: 9001161
[TBL] [Abstract][Full Text] [Related]
20. Intranasal salmon calcitonin in postmenopausal osteoporosis: effect of different therapeutic regimens on vertebral and peripheral bone density.
Perrone G; Galoppi P; Valente M; Capri O; D'Ubaldo C; Anelli G; Zichella L
Gynecol Obstet Invest; 1992; 33(3):168-71. PubMed ID: 1612530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
